Statin therapy is associated with reduced restenosis rates after coronary stent implantation in carriers of the PlA2 allele of the platelet glycoprotein IIIa gene

European Heart Journal

Volumn 22, Issue 7, 2001, Pages 587-595

  Walter, D H ^a   Schachinger V ^a   Elsner, M ^a   Mach, S ^a   Dimmeler, S ^a   Auch Schwelk, W ^a   Zeiher, Andreas M ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Glycoproteins; Platelets; Restenosis; Statin; Stents

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; CERIVASTATIN; CHOLESTEROL; FIBRINOGEN RECEPTOR; FLUINDOSTATIN; GLYCOPROTEIN IIIA; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

ADULT; AGED; ALLELE; ARTERY INTIMA PROLIFERATION; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CORONARY STENT; DRUG EFFECT; DRUG MECHANISM; FEMALE; GENETIC POLYMORPHISM; HEART DEATH; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HUMAN; INCIDENCE; INTIMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RESTENOSIS; THROMBOCYTE; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; ANTICHOLESTEREMIC AGENTS; CORONARY ANGIOGRAPHY; FEMALE; GRAFT OCCLUSION, VASCULAR; HUMANS; MALE; MIDDLE AGED; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; STENTS;

EID: 0034930568     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.2000.2313     Document Type: Article

References (34)

1. A comparison of coronary-artery stenting with angioplasty for isolated stenosis of the proximal left anterior descending coronary artery
2. A randomized comparison of coronary stent placement and balloon angioplasty in the treatment of coronary artery disease
3. A comparison of balloon expandable stent implantation with balloon angioplasty in patients with coronary artery disease
4. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents
5. Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study
6. Stent restenosis. Can effective antithrombotic therapy be protective?
7. Frequency and severity of cyclic flow alterations and platelet aggregation predict the severity of neointimal proliferation following experimental coronary stenosis and endothelial injury
8. Cellular adhesion: GPIIb/IIIa as a prototypic adhesion receptor
9. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis
10. Platelet glycoprotein IIIa polymorphisms and risk of coronary stent thrombosis
11. A polymorphism of platelet glycoprotein IIIa and risk of restenosis after coronary stent placement
12. A2 polymorphism
13. Antiatherothrombotic properties of statins: Implications for cardiovascular event reduction
14. Effect of statin therapy on restenosis after coronary stent implantation
15. Assessment of short-, medium-, and long-term variations in arterial dimensions from computer-assisted quantitation of coronary cineangiograms
16. Adjunctive intracoronary infusion of antithrombin III during percutaneous transluminal coronary angioplasty: Results of a prospective, randomized trial
17. Glycoprotein IIIa polymorphism and risk of myocardial infarction
18. Predictive factors of restenosis after coronary stent placement
19. Statin trials and goals of cholesterol-lowering therapy
20. Platelet function in hyperlipoproteinemia
21. Platelet-dependent thrombin generation in patients with hyperlipidemia
22. Pravastatin therapy in hyperlipidemia: Effects on thrombus formation and the systemic hemostatic profile
23. Hyperlipidemia and coronary heart disease: Correction of the increased thrombogenic potential with cholesterol reduction
24. Inhibition of proliferation of arterial smooth-muscle cells by fluvastatin
25. Suppression of neointimal thickening by a newly developed HMG-CoA reductase inhibitor. BAYw626, and its inhibitory effect on vascular smooth muscle cell growth
26. Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys
27. The effect of cholesterol lowering, and antioxidant therapy on endothelium-dependent coronary vasomotion
28. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease
29. A polymorphism in young men with myocardial infarction
30. A1/A2 polymorphism of platelet glycoprotein IIIa and risk of myocardial infarction, stroke, and venous thrombosis
31. A1/A2 polymorphism and association with excess procedural risk for coronary catheter interventions: A case-controlled study
32. A1A2 polymorphism of glycoprotein IIIa and risk of coronary artery disease and restenosis following coronary angioplasty
33. Comparative effect of pravastatin and simvastatin on platelet thrombus formation in hypercholesterolemic coronary patients
34. Lipid-lowering therapy reduces blood thrombogenicity in hypercholesterolemic patients: Effect of simvastatin